Streptokinase-prostacyclin--nitric oxide: in vivo interactions.
Gryglewski
R J
RJ
Chair of Pharmacology, Medical College of Jagiellonian University, Cracow, Poland.
Swies
J
J
D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D002415:Cats; D011464:Epoprostenol / Q000008:administration & dosage / Q000494:pharmacology*; D005112:Extracorporeal Circulation; D005342:Fibrinolysis / Q000187:drug effects*; D006497:Heparan Sulfate / Q000008:administration & dosage / Q000494:pharmacology; D016285:Iloprost / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008981:Molsidomine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology; D019335:Nitroarginine; D010974:Platelet Aggregation / Q000187:drug effects; D013300:Streptokinase / Q000008:administration & dosage / Q000494:pharmacology*; D013927:Thrombosis / Q000503:physiopathology*; D014665:Vasodilator Agents / Q000494:pharmacology
D001120:Arginine; D001241:Aspirin; D011464:Epoprostenol; D006497:Heparan Sulfate; D016285:Iloprost; D008981:Molsidomine; D009569:Nitric Oxide; D019335:Nitroarginine; D013300:Streptokinase; D014665:Vasodilator Agents; C002385:linsidomine